Brief review of current research in FXS: implications for treatment with psychotropic medication.
The purpose of this paper is to provide a brief review of current research in fragile X syndrome (FXS) with regards to the morphology and behavioral phenotype associated with FXS and the use of psychotropic medication for the treatment of behavior problems (e.g., aggression) often seen in FXS (full mutation). The lack of production of the fragile X mental retardation protein (FMRP) is associated with FXS and has been found to result in various neuronal changes such as altered dendritic morphology and function as well as altered neurotransmitter functions. A review of the basic literature on animal models and the relevance of these findings for the use of psychotropic treatment of problem behaviors in FXS will be discussed. Future research directions will be presented.
Valdovinos
Maria G
MG
Drake University, Psychology Department, 2507 University Avenue, Des Moines, IA 50311, United States. maria.valdovinos@drake.edu
D000818:Animals; D035843:Biomedical Research / Q000639:trends*; D002986:Clinical Trials as Topic / Q000639:trends*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000639:trends*; D005600:Fragile X Syndrome / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D016896:Treatment Outcome
D011619:Psychotropic Drugs